1. Home
  2. MGNX vs CURV Comparison

MGNX vs CURV Comparison

Compare MGNX & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.88

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

HOLD

Current Price

$1.09

Market Cap

102.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
CURV
Founded
2000
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
102.2M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
MGNX
CURV
Price
$1.88
$1.09
Analyst Decision
Hold
Hold
Analyst Count
5
6
Target Price
$3.20
$1.59
AVG Volume (30 Days)
533.9K
179.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.36
EPS
N/A
0.01
Revenue
$149,962,000.00
$1,103,737,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$101.00
Revenue Growth
155.26
N/A
52 Week Low
$0.99
$0.94
52 Week High
$2.49
$6.95

Technical Indicators

Market Signals
Indicator
MGNX
CURV
Relative Strength Index (RSI) 57.06 49.54
Support Level $1.62 $0.96
Resistance Level $1.97 $1.13
Average True Range (ATR) 0.09 0.07
MACD 0.02 0.00
Stochastic Oscillator 67.47 70.00

Price Performance

Historical Comparison
MGNX
CURV

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.

Share on Social Networks: